This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rotheneder, A.
Right arrow Articles by Weiss, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rotheneder, A.
Right arrow Articles by Weiss, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2002, p. 2010-2013, Vol. 46, No. 6
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.6.2010-2013.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Effects of Synthetic Siderophores on Proliferation of Plasmodium falciparum in Infected Human Erythrocytes

Andrea Rotheneder,1 Gernot Fritsche,1 Lothar Heinisch,2 Ute Möllmann,2 Susanne Heggemann,2 Clara Larcher,3 and Günter Weiss1*

Department of Internal Medicine, University Hospital of Innsbruck,1 Institute for Hygiene and Social Medicine, University of Innsbruck, A-6020 Innsbruck, Austria,3 Hans-Knöll Institute for Natural Product Research, Jena, Germany2

Received 3 December 2001/ Returned for modification 4 January 2002/ Accepted 6 March 2002


arrow
ABSTRACT
 
Because iron is essential for Plasmodium falciparum, we investigated the in vitro potential of various synthetic siderophores to kill P. falciparum in infected human erythrocytes. The substances with the most promising profile, i.e., low 50% lethal doses for plasmodia and minimum toxicity towards mammalian cells, were siderophores with an acylated monocatecholate or a triscatecholate as substituent.


arrow
TEXT
 
The spread of drug resistance among Plasmodium falciparum strains is a global health concern. Many antimalarial drugs affect the release of iron from hemoglobin by the parasite. The importance of iron for the clinical course of malaria has been shown in several studies (5, 9). Since the malaria parasite is dependent on a sufficient supply of iron, compounds that induce iron deprivation are potentially useful antimalarial agents (10, 11). Chelators suppress parasite growth by affecting iron availability within the parasite (8, 14), presumably by interfering with hemoglobin breakdown (3).

This resulted in placebo-controlled studies investigating the effect of the iron chelator desferrioxamine B (DFO B) on the clinical course of P. falciparum infection (4). Although these studies showed some clinical benefit, the overall mortality was not reduced (16). However, these studies suggested that iron deprivation is a useful therapeutic approach for malaria. Moreover, the hydrophilic DFO B displays poor permeation across membranes (8) and thus is relatively slow in eliciting biological effects on intracellular parasites (17).

Since the degree of antimalarial activity seems to correlate with the degree of lipophilicity, i.e., the ability of the compounds to cross over cell membranes (1, 7, 15, 19), the identification of new iron-chelating substances with improved pharmacokinetics may increase the antimalarial efficacy of the drugs. This strategy is exemplified by a class of synthetic hydrophobic siderophores which feature an iron(III)-binding cavity mimicking that of ferrichrome or by N-terminal derivatives of DFO, which fully retain the iron-binding capacity of the parent compound.

We examined artificial synthetic siderophores as monocatecholates (dihydroxybenzoates) containing aminobenzoic acid (Fig. 1, compound 7), amino acids (compounds 8 to 10), and hydrazones of glyoxylic acid (compounds 1 and 2), phenylglyoxylic acid (compounds 3 and 6), or formylbenzoic acids (compounds 4 and 5) as scaffold or as triscatecholates based on triamines (compounds 11 to 16) and tris-aminopropyl-methyl-{alpha}-D-glucopyranoside (compounds 17 and 18), possessing one or three catecholate moieties, respectively, as chelating groups. The catecholate moieties were used as free catecholates in the 2,3-OH derivatives (compounds 1, 3, 4, 5, 11, 12, and 13) and the 3,4-OH derivative (compound 2), as acylated catecholates in the 2,3-OCOCH3 derivatives (compounds 7 and 17) and the 3,4-OCOOCH3 derivative (compound 6), or in heterocyclic form as 2,4-dioxo-1,3-benzoxazine derivatives (compounds 8, 9, 14, 15, 16, and 18). The acylated catecholates possess higher lipophilic properties. For iron chelation these compounds have to be cleaved by acylases to the free catecholates. Iron complexes need three catecholate groups, corresponding to one molecule of triscatecholate or three molecules of monocatecholates. The triscatecholate is a trimer of N-2,3-dihydroxybenzoyl L-serine with an unstable trilactone backbone. The structures of these siderophores are given in Fig. 1.



View larger version (24K):
[in this window]
[in a new window]
  		FIG. 1. Structures of the synthetic siderophores 1 to 18 used in the study. Ac = COCH3; Moc = COOCH3.

The following compounds were synthesized according to the literature: compounds 4, 7, 6, 8, and 9 (18); compounds 1 and 2 (12); compounds 11, 12, 13, 15, and 16 (13); and compounds 17 and 18 (6).

As standards for comparison, we used the iron chelators DFO (Sigma, Munich, Germany) and dexrazoxane (ICRF-187).

The culture of P. falciparum was carried out exactly as described elsewhere (2).

The modulation of parasite growth by the different siderophores was studied by adding increasing concentrations of the respective drugs to human erythrocytes infected with P. falciparum. The relative parasitemia was evaluated by preparing blood smears after an incubation period of 24 h with the respective drugs, and a 50% lethal dose (LD50) was calculated for each substance investigated by comparing these results with the counts obtained for untreated control samples. None of the solvents used for the siderophores, i.e., dimethyl sulfoxide or dimethylformamide, altered parasitemia compared to that for untreated controls (data not shown).

To assess the toxicity towards mammalian cells, we studied the effects of the siderophores on viability of K562 cells. K562 cells were incubated with increasing concentrations of the respective siderophores for 24 h. Then, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; 5 mg/ml; Sigma) was added, and after another 4 h, 200 µl of dimethyl sulfoxide was used to solubilize the colored formazan product, which was then quantified with an enzyme-linked immunosorbent assay reader. An MTT value of 100% indicates that the respective siderophore did not reduce cell viability compared to that for untreated control cells, whereas an MTT value of 10% indicates that 90% of cells died compared to the control.

All substances tested exerted toxic effects towards P. falciparum (Table 1). LD50s greatly varied and were not obviously different between monocatechol- and triscatechol-substituted siderophores. However, the antiplasmodial activity of the respective parent catecholates was greatly affected by the different derivatives. The monocatecholates based on aminobenzoic acid (compound 7) or hydrazones of glyoxylic acid, phenylglyoxylic acid, or formylbenzoic acid (compounds 1, 3, 5, and 6) with 2,3-OH or 2,3-O-acylated and benzoxazine substituents showed good antiplasmodial activity (LD50 <= 10 µM), except for compound 4. The monocatecholate with a 3,4-OH substituent (compound 2) was less toxic. The monocatecholate compounds 8 and 9—based on amino acids—were also highly active. The triscatecholates based on triamines exhibited good antiparasitic activity, especially compound 11, with 2,3-OH substituents and a shorter backbone triaminopropylamine, while the corresponding compound 13, with a longer triamine backbone, was less active. The most active compounds were the triscatecholates based on glucopyranoside, which were the most lipophilic drugs (compound 17). Overall, the antiplasmodial activities of these compounds were consistently at least equal to that of DFO and, in one case (compound 17), >1,000-fold greater.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Siderophores and iron chelators investigateda

In parallel, we tested the siderophores for potential toxicity towards mammalian cells by means of the MTT assay. The substances with the most promising profile, i.e., low LD50s for plasmodia and hardly any toxicity towards mammalian cells at these concentrations, were mono- and triscatecholates with O-acyl and 2,3-OH substitutions (compounds 1, 3, 6, 7, 11, and 17 [Table 1]).

Interestingly, iron salts at low concentrations (20 µM) were able to reverse the antiparasitic effects of most triscatechol-containing compounds, suggesting that their antiparasitic effect may be primarily due to limitation of cellular iron availability. In contrast, the toxicity towards P. falciparum exerted by most monocatechol substances was not affected by exogenous iron salts (Table 1). This indicates that the antiparasitic effect of these substances is independent of the interaction with the intracellular iron pool and may be due to alternative mechanisms, e.g., direct attack of essential enzymes within the plasmodia or interference with iron release from hemoglobin.

In general it also appeared that siderophore compounds with the potential to chelate iron exerted increased toxicity towards mammalian cells (Table 1).

We have identified a number of siderophores with good antiplasmodial activity and low toxicity towards mammalian cells. However, the potential of the various substances to eliminate the parasite differed as a function of catecholate substitutions, of the basic structures, and of lipophilicity. Moreover, the mode of action may differ between monocatechols and triscatechol derivatives, with the latter primarily acting as iron chelators. Based on the present results, more-detailed structure-activity correlations need to be studied with new directed synthesized derivatives.

However, the antiplasmodial activity of all tested siderophores was higher than that of DFO B, a compound which has been used for treatment of human malaria. Thus, investigations of the most promising compounds identified in our study in murine models for malaria may be an attractive approach in the search for new antimalarials.


arrow
ACKNOWLEDGMENTS
 
A.R. and G.F. contributed equally to the work presented here.

This work was supported by a grant from the Austrian research funds FWF, project 14215.

We thank Peter Kremsner, Tübingen, Germany, for providing malaria parasites and Harald Schennach, Innsbruck, Austria, for supplying human erythrocytes.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Internal Medicine, University Hospital, Anichstr. 35, A-6020 Innsbruck, Austria. Phone: 43-512-504-3255. Fax: 43-512-504-3293. E-mail: guenter.weiss{at}uibk.ac.at. Back


arrow
REFERENCES
 
    1
  1. Cabantchik, Z. I., H. Glickstein, J. Golenser, M. Loyevsky, and A. Tsafack. 1996. Iron chelators: mode of action as antimalarials. Acta Haematol. 95:70-77.[Medline]
    2. 2
  2. Fritsche, G., C. Larcher, H. Schennach, and G. Weiss. 2001. Regulatory interactions between iron and nitric oxide metabolism for immune defense against Plasmodium falciparum infection. J. Infect. Dis. 183:1388-1394.[CrossRef][Medline]
    3. 3
  3. Gabay, T., and H. Ginsburg. 1993. Hemoglobin denaturation and iron release in acidified red blood cell lysate—a possible source of iron for intraerythrocytic malaria parasites. Exp. Parasitol. 77:261-272.[CrossRef][Medline]
    4. 4
  4. Gordeuk, V., P. Thuma, G. Brittenham, C. McLaren, D. Parry, A. Backenstose, G. Biemba, R. Msiska, L. Holmes, and E. McKinley, et al. 1992. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N. Engl. J. Med. 327:1473-1477.[Abstract]
    5. 5
  5. Harvey, P. W., P. F. Heywood, M. C. Nesheim, K. Galme, M. Zegans, J. P. Habicht, L. S. Stephenson, K. L. Radimer, B. Brabin, and K. Forsyth, et al. 1989. The effect of iron therapy on malarial infection in Papua New Guinean schoolchildren. Am. J. Trop. Med. Hyg. 40:12-18.
    6. 6
  6. Heggemann, S., M. Schnabelrauch, D. Klemm, U. Mollmann, R. Reissbrodt, and L. Heinisch. 2001. New artificial siderophores based on a monosaccharide scaffold. Biometals 14:1-11.[CrossRef][Medline]
    7. 7
  7. Hershko, C., E. N. Theanacho, D. T. Spira, H. H. Peter, P. Dobbin, and R. C. Hider. 1991. The effect of N-alkyl modification on the antimalarial activity of 3-hydroxypyridin-4-one oral iron chelators. Blood 77:637-643.[Abstract/Free Full Text]
    8. 8
  8. Loyevsky, M., S. D. Lytton, B. Mester, J. Libman, A. Shanzer, and Z. I. Cabantchik. 1993. The antimalarial action of desferal involves a direct access route to erythrocytic (Plasmodium falciparum) parasites. J. Clin. Investig. 91:218-224.
    9. 9
  9. Murray, M. J., A. B. Murray, M. B. Murray, and C. J. Murray. 1978. The adverse effect of iron repletion on the course of certain infections. Br. Med. J. 2:1113-1115.
    10. 10
  10. Peto, T. E., and J. L. Thompson. 1986. A reappraisal of the effects of iron and desferrioxamine on the growth of Plasmodium falciparum ‘in vitro’: the unimportance of serum iron. Br. J. Haematol. 63:273-280.[Medline]
    11. 11
  11. Pollack, S., R. N. Rossan, D. E. Davidson, and A. Escajadillo. 1987. Desferrioxamine suppresses Plasmodium falciparum in Aotus monkeys. Proc. Soc. Exp. Biol. Med. 184:162-164.[CrossRef][Medline]
    12. 12
  12. Reissbrodt, R., L. Heinisch, U. Mollmann, W. Rabsch, and H. Ulbricht. 1993. Growth promotion of synthetic catecholate derivatives on Gram-negative bacteria. Biometals 6:155-162.
    13. 13
  13. Schnabelrauch, M., S. Wittmann, K. Rahn, U. Mollmann, R. Reissbrodt, and L. Heinisch. 2000. New synthetic catecholate-type siderophores based on amino acids and dipeptides. Biometals 13:333-348.[CrossRef][Medline]
    14. 14
  14. Scott, M. D., A. Ranz, F. A. Kuypers, B. H. Lubin, and S. R. Meshnick. 1990. Parasite uptake of desferroxamine: a prerequisite for antimalarial activity. Br. J. Haematol. 75:598-602.[Medline]
    15. 15
  15. Shanzer, A., J. Libman, S. D. Lytton, H. Glickstein, and Z. I. Cabantchik. 1991. Reversed siderophores act as antimalarial agents. Proc. Natl. Acad. Sci. USA 88:6585-6589.[Abstract/Free Full Text]
    16. 16
  16. Thuma, P. E., G. F. Mabeza, G. Biemba, G. J. Bhat, C. E. McLaren, V. M. Moyo, S. Zulu, H. Khumalo, P. Mabeza, A. M'Hango, D. Parry, A. A. Poltera, G. M. Brittenham, and V. R. Gordeuk. 1998. Effect of iron chelation therapy on mortality in Zambian children with cerebral malaria. Trans. R. Soc. Trop. Med. Hyg. 92:214-218.[CrossRef][Medline]
    17. 17
  17. Whitehead, S., and T. E. Peto. 1990. Stage-dependent effect of deferoxamine on growth of Plasmodium falciparum in vitro. Blood 76:1250-1255.[Abstract/Free Full Text]
    18. 18
  18. Wittmann, S., I. Scherlitz-Hofmann, U. Mollmann, D. Ankel-Fuchs, and L. Heinisch. 2000. 8-Acyloxy-1,3-benzoxazine-2,4-diones as siderophore components for antibiotics. Arzneimittelforschung 50:752-757.[Medline]
    19. 19
  19. Yinnon, A. M., E. N. Theanacho, R. W. Grady, D. T. Spira, and C. Hershko. 1989. Antimalarial effect of HBED and other phenolic and catecholic iron chelators. Blood 74:2166-2171.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, June 2002, p. 2010-2013, Vol. 46, No. 6
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.6.2010-2013.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rotheneder, A.
Right arrow Articles by Weiss, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rotheneder, A.
Right arrow Articles by Weiss, G.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»